When NOD ligands become antidotes.

Area of Science:

• Microbiology
• Immunology
• Gastroenterology

Background:

• Loss-of-function mutations in NOD2 (nucleotide-binding oligomerization domain-containing protein 2) are a known genetic risk factor for Crohn's disease (CD).
• NOD2 plays a crucial role in sensing bacterial muropeptides from the gut microbiota.
• Dysregulation of NOD2 signaling contributes to chronic intestinal inflammation characteristic of CD.

Purpose of the Study:

• To identify microbial factors that modulate NOD2 activity and intestinal inflammation.
• To investigate the therapeutic potential of targeting microbiota-derived molecules in Crohn's disease.

Main Methods:

• Utilized microbial screening to identify enzymes impacting NOD2 signaling.
• Employed cellular assays and in vivo models to assess the anti-inflammatory effects of the identified enzyme.

Main Results:

• Identified a novel microbiota-derived peptidoglycan remodeling enzyme.
• Demonstrated that this enzyme dampens chronic intestinal inflammation by acting through the NOD2 receptor.
• Showcased the enzyme's potential to alleviate disease severity in preclinical models.

Conclusions:

• A specific microbial enzyme can modulate NOD2 signaling to reduce intestinal inflammation.
• This enzyme represents a potential therapeutic target for managing Crohn's disease.
• Targeting microbiota-derived factors offers a promising strategy for CD treatment.